Literature DB >> 20107976

The effects of strontium ranelate on biochemical markers of bone turnover and their relationship with bone mineral density.

J Stepan, S Ish-Shalom, F Hawkins, F Marín, J Farrerons, G Kapetanos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20107976     DOI： 10.1007/s00198-009-1157-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  5 in total

1.  Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

Authors:  J Y Reginster; E Seeman; M C De Vernejoul; S Adami; J Compston; C Phenekos; J P Devogelaer; M Diaz Curiel; A Sawicki; S Goemaere; O H Sorensen; D Felsenberg; P J Meunier
Journal:  J Clin Endocrinol Metab       Date:  2005-02-22       Impact factor: 5.958

2.  Effect of long-term treatment with strontium ranelate on bone strontium content.

Authors:  Olaf Bärenholdt; Niels Kolthoff; Stig Pors Nielsen
Journal:  Bone       Date:  2009-04-17       Impact factor: 4.398

3.  Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years.

Authors:  O Bruyère; J Collette; R Rizzoli; C Decock; S Ortolani; C Cormier; J Detilleux; J-Y Reginster
Journal:  Osteoporos Int       Date:  2009-10-08       Impact factor: 4.507

4.  The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.

Authors:  Pierre J Meunier; Christian Roux; Ego Seeman; Sergio Ortolani; Janusz E Badurski; Tim D Spector; Jorge Cannata; Adam Balogh; Ernst-Martin Lemmel; Stig Pors-Nielsen; René Rizzoli; Harry K Genant; Jean-Yves Reginster
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245

5.  Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

Authors:  Robert R Recker; Fernando Marin; Sophia Ish-Shalom; Rüdiger Möricke; Federico Hawkins; Georgios Kapetanos; María P de la Peña; Jörn Kekow; Jordi Farrerons; Beatriz Sanz; Heide Oertel; Jan Stepan
Journal:  J Bone Miner Res       Date:  2009-08       Impact factor: 6.741
  5 in total
  2 in total

1.  The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years.

Authors:  E T Middleton; S A Steel; M Aye; S M Doherty
Journal:  Osteoporos Int       Date:  2011-01-28       Impact factor: 4.507

Review 2.  How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis.

Authors:  P J Marie; D Felsenberg; M L Brandi
Journal:  Osteoporos Int       Date:  2010-09-02       Impact factor: 4.507
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.